drug_type
RELEVANT_DRUG
intervention_type
Biological: Genetically engineered cellular therapy (CAR-NK)
drug_description
Natural killer cells genetically engineered to express a chimeric antigen receptor using the NKG2D ectodomain, enabling recognition of stress-induced ligands (MICA, MICB, ULBP1–6) on tumor cells and triggering NK activation, degranulation (perforin/granzyme), cytokine release, and death receptor–mediated apoptosis. Administered as two IV infusions on days 2–3 after each chemotherapy cycle with dose escalation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Genetically engineered NK cells expressing an NKG2D-based chimeric antigen receptor bind stress-induced ligands (MICA, MICB, ULBP1–6) on tumor cells, triggering NK activation with degranulation (perforin/granzyme), cytokine release, and death receptor–mediated apoptosis (e.g., TRAIL/Fas) to kill tumor cells.
drug_name
NKG2D CAR-NK cells
nct_id_drug_ref
NCT06503497